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Abstract
Background: Intratumoral and circulating regulatory T cells (Tregs) have been shown to be critical in the
pathogenesis of hepatocellular carcinoma (HCC). However there is limited knowledge on the alterations of
regulatory B cells (Bregs). We here investigated perioperative dynamic alterations of peripheral circulating Tregs and
Bregs in HCC patients to reveal the relationship between regulatory lymphocytes and its clinical implications.
Methods: 36 patients with HCC, 6 with chronic hepatitis B infection and 10 healthy donors were enrolled for this
study. Frequencies of peripheral Tregs and Bregs were measured by flow cytometry with antibodies against CD4,
CD25, CD127, CD19 and IL-10 before, and after radical surgery. Then, clinical informatics of HCC patients was
achieved through Digital Evaluation Score System (DESS) for the assessment of disease severity. Finally, we
analysed correlations between digitalized clinical features and kinetics of circulating regulatory lymphocytes.
Results: Level of circulating CD4
+CD25
+CD127
- Tregs in HCC patients was significantly lower than that in healthy
donors and patients with chronic hepatitis B infection before surgery, but was increased after surgery. Preoperative level
of CD19
+ IL-10
+ Bregs in HCC patients was also significantly lower than the other groups. However it dramatically was
elevated right after surgery and remained elevated compared to controls (about 7 days after surgery, P =0 . 0 4 ) .
Frequency of circulating Tregs was correlated with circulating leukocytes, ferritin, and clinical features suggesting tumor
aggressiveness including portal vein thrombosis, hepatic vein involvement and advanced clinical stages. Frequency of
circulating Bregs was associated with Hepatitis B e Antigen (HBeAg) and Hepatitis B virus (HBV) DNA copy number. In
addition, DESS was significantly and positively correlated with other staging systems.
Conclusion: Frequencies of peripheral Tregs and Bregs in HCC patients increased after surgery. These results
suggest that a postoperative combination of therapies against Tregs and Bregs may be beneficial for better
outcome of HCC patients after resection.
Keywords: regulatory T cells, regulatory B cells, hepatocellular carcinoma, surgery, dynamic alteration, lymphocytes,
clinical informatics
Background
Regulatory T cells (Tregs) are a subpopulation of CD4
+
and CD8
+ T cells with immune suppressive function. In
cancer patients especially patients with hepatocellular
carcinoma (HCC), Tregs contribute to the dampening of
the antitumor immune response [1,2]. Patients under-
going hepatic resection for HCC with prominent Treg
infiltration showed increased recurrence and worse
prognosis. Intratumoral Tregs have further been pro-
posed to be an independent prognostic factor in HCC
patients by several publications. In combination with
cytotoxic T cells, Tregs can predict prognosis more
effectively [3,4]. In addition, increased CD4
+CD25
+
Tregs in the tumor microenvironment of HCC were
found to be correlated with tumor size and vascular
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f i r s tr e p o r t e dp e r i p h e r a lC D 4
+CD25
+Tregs were
increased in HCC patients [6]. However, contradict
results were also described by others [7].
Recently, regulatory B cells (Bregs), a new family of
regulatory cells, were found to control immune
responses at both innate and adaptive levels [8,9].
Expansion of Bregs was demonstrated to inhibit harmful
immune responses in chronic inflammation by deactiva-
tion of effector T cells and natural Killer T cells [10,11].
Furthermore, the suppressive immune function of Bregs
appears to be in contact-dependent and independent
manner [12]. These immune regulatory mechanisms
comprise of protection from lethal inflammation, modu-
lation of the development of autoimmune diseases
[13-15], and inhibition of anti-cancer response in var-
ious tumor models [9,16-18]. However, few studies
assess the role of Bregs in HCC development.
Although compelling evidence has suggested the
important roles of both Tregs and Bregs in tumor devel-
opment, few researches described both of them together
in HCC patient samples. In the present study, we inves-
tigated perioperative alterations of both circulating
T r e g sa n dB r e g si np a t i e n t sw i t hH C Ca n dt h e i rr e l a -
tions to clinical phenotypes were examined. Clinical
phenotypes, as clinical informatics, were achieved by a
Digital Evaluation Score System (DESS) for assessing the
severity of patients [19]. Frequencies of both circulating
Tregs and Bregs elevated after surgery. These results
suggest that a combined deletion of both Tregs and
Bregs may be essential for better prognosis of patients
with HCC after surgery. We also found significant cor-
relations between digitalized clinical features and both
peripheral regulatory lymphocytes. Integration of clinical
informatics and experimental results is a useful method
to conduct translational research.
Methods
Patient Population
Of 230 candidates from outpatients and inpatients, the
current case-controlled study recruited 36 patients with
primary liver cancer, 6 with chronic Hepatitis B infec-
tion (CHB) as chronic liver disease control, and 10
healthy donors as normal controls. None of patients
with liver cancer received any invasive treatments like
transcatheter arterial chemoembolisation or radiation
frequency ablation before tumor resection. Among
patients with liver cancer, 32 were pathologically diag-
nosed as hepatocellular carcinoma, while 4 as combina-
tion of hepatocellular and cholangiocarcinoma.
Additionally, patients with chronic HBV infection
enrolled were Hepatitis B Surface Antigen-positive for
greater than 6 months according to its definition [20].
Based on clinicapathological features, patients were
divided into different clinical stages by tumor node
metastasis (TNM) staging system [21]. This project was
approved by the Ethical Committee of First Affiliated
Hospital of School of Medicine of Zhejiang University
(NO.2011-108) and conducted in compliance with the
Helsinki Declaration. All the participants were explained
the investigative nature of the study and signed an
informed consent before entry into study.
Samples collection and preparation
Peripheral blood samples werei n t r a v e n o u s l yd r e wa n d
collected. Samples were collected immediately after
admission before any intervention, 1-2 days and about 7
(5-9) days after tumor resection. Samples of patients
with chronic HBV infection were collected when patient
were just admitted without therapeutic intervention.
Peripheral blood mononuclear cells (PBMC) were iso-
lated according to previously study [22,23]. In brief,
whole blood samples were overlaid onto Ficoll separa-
tion media (Shanghai Danfan Network Science & Tech-
nology, Shanghai, China) after 1:1 dilution with Hank’s
Balanced Salted Solution (Gibco, CA, USA). PBMC were
centrifuged for 20 min at X1900 rpm, collected at the
plasma interface and washed thrice after centrifugation
at X1000 rpm for 10 min. PBMC were frozen and stored
in liquid nitrogen till flow cytometry analysis.
Flow cytometry analysis
Flow cytometry analysis was conducted by FACS Aria II
flow cytometer (BD Bioscience, San Diego, CA, USA).
For surface staining, suspensions of PBMC were stained
on ice using predetermined optimal concentrations of
each antibody for 30 min, and fixed using fixation buffer
(BD PharMingen, San Diego, CA). Tregs identified with
CD4
+CD25
+CD127
- expression were stained with
human regulatory T cell Cocktail (BD PharMingen) [24]
and Bregs identified with IL10
+CD19
+ expression were
stained with human anti-CD19 PerCp-Cy5.5 and
Human anti-IL10 PE (BD PharMingen) [25]. Intracellu-
lar IL-10 analysis was performed by flow cytometry, as
described previously [25,26]. Briefly, cells were resus-
pended (2 × 10
6 cells/ml) in medium and stimulated
with CpG (Invivogen, San Diego, CA) and CD40L (1
μg / m l ;R & DS y s t e m s ,M i n n e a p o l i s ,M N ) ,P h o r b o l - 1 2 -
myristate-13-acetate (PMA,50 ng/ml; Sigma), ionomycin
(1 μg/ml; Sigma), Brefeldin A (1X solution/ml; BD
Bioscience) right before staining and flow cytometry
analysis. After surface staining, for IL-10 detection, Fc
receptors were blocked using FcR-Binding inhibitor
(eBioscience, San Diego, CA). Cells were fixed, permea-
bilized using a Cytofix/Cytoperm kit (BD PharMingen),
and stained with monoantibody against IL-10 according
to the manufacturer’s instructions. Results are expressed
as the frequency of Tregs or Bregs.
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Digital Evaluation Score System (DESS) for patients with
HCC was designed and implicated, as described previously
with slight modifications [19]. DESS was established by
senior surgeons who are specialized in hepatobiliary and
pancreas disease to switch clinical pearls and materials of
HCC patients into digitalized information. Briefly, DESS
was integrated with descriptive information of patient his-
tory, signs, physical examination, clinical imaging, and
pathology and laboratory tests. Of them, 165 clinical vari-
ables selected from HCC patients were included in DESS
and divided into different sections such as history (Addi-
tional file 1 Table S1), signs and physical examination
(Additional file 2, Table S2), combined laboratory test
(Additional file 3 Table S3), imaging (Additional file 4
Table S4) and pathology (Additional file 5 Table S5).
Severity of each variable was scored and calculated as 0, 1,
2 and 4 (Additional file 1, 2, 3, 4). The maximal value of
score 4 means far more above physiological range or
much more critical condition, while the minimal value of
score 0 indicates the variable is within physiological range.
Several variables were 0 or 4 like “fatigue”, “enlargement
of lymph nodes” and “goblin”, because they are either lack
of standard discrimination criteria or subdivision relies too
much on patient’so rp h y s i c i a n ’s personal judgment. The
value of 3 was specially excluded, since exponential values
could better amplify distance among different severity
levels [19]. Variables of laboratory tests in DESS were
scored on basis of the results of preoperative measure-
ments after patient admission without clinical treatment.
After clinical data was transformed into points of each
variable and put them together, the total score of DESS
ranged from 0 to 660 points, higher scores in our design
indicate a severer condition.
Data analysis
All values were expressed as mean ± SEM. Statistical
analysis was applied by SPSS software (SPSS 18.0; SPSS
Inc; Chicago, IL). Frequencies of peripheral Tregs and
Bregs among groups were analysed with one way
ANOVA, followed by an unpaired student’s t-test.
Ranked data as single variable scores of DESS was com-
pared by Mann-Whitney test. Correlations between
DESS scores and frequencies of Tregs and Bregs and
between the frequency of circulating total lymphocytes
and that of Tregs and Bregs were performed by Spear-
man’s rho test and Pearson’s test as appropriate. P <
0.05 was considered as statistically significant.
Results
Perioperative alterations of peripheral Tregs and Bregs
Frequency of peripheral Tregs in HCC patients before
surgery were significantly lower than that in the healthy
(P = 0.002; Figure 1B) and CHB patients (P =0 . 0 2 ;
Figure 1B). 1-2 days after surgery, frequency of Tregs
was not different to the original level (P = 0. 43). How-
ever, a significant elevation of frequency of Tregs was
observed about 7 days after tumor resection, as com-
pared with that before the operation (1.38 ± 0.12% in
HCCa7 versus 1.14 ± 0.09% in HCCb, P = 0.04; Figure
1). Frequency of Tregs of HCC patients about 7 days
after surgery was similar to that of patients with CHB (P
= 0.19) though still lower than the healthy (P = 0.047).
Frequencies of Bregs in the patients with CHB were signifi-
cantly higher than those in the healthy and preoperative HCC
patients (P < 0.05; Figure 2). Frequency of Bregs of HCC
patients was significantly elevated by time after tumor resec-
tion (1.88 ± 0.23% in HCCa1 versus 3.48 ± 0.53% in HCCa7,
P < 0.001; Figure 2), even significantly higher than that in
CHB patients (HCCa7 versus CHB, P = 0.04; Figure 2).
Circulating kinetics of lymphocytes with Tregs and Bregs
Frequency and number of circulating lymphocytes of
HCC patients considerably declined 1-2 days after
Figure 1 Frequencies of peripheral regulatory T cells of
different study groups. Frequencies of peripheral regulatory T cells
were analysed in the healthy donor (Healthy), patients with chronic
hepatitis B infection (CHB), and patients with hepatocellular
carcinoma (HCC) before surgery (HCCb), 1-2 days (HCCa1) or about
7 days (HCCa7) after surgery. Representative flow cytometry analysis
of peripheral CD4
+CD25
+CD127
- populations were measured and
presented (A). Frequency of CD4
+CD25
+CD127
- cells of total CD4
+ T
cells in the peripheral blood were calculated (B). The mean ± SEM is
shown,* and ** stand for P < 0.05 and 0.01, respectively.
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0.01; Figure 3). However, it significantly elevated about
7 days after surgery, comparing with that 1-2 days after
surgery (P < 0.001; Figure 3). The number of circulating
lymphocytes about 7 days after surgery had no differ-
ence from the preoperative level. Frequency of circulat-
ing lymphocytes was correlated with the frequency of
Tregs to some extent (r = 0.263, P = 0.028).
Acquisition of General features of study population
through DESS
All HCC patients (n = 36) were performed radical hepatic
resection. Clinical informatics of HCC patients was digita-
lized through DESS as introduced in Methods. The mean
value of HCC Patients’ total score was 102.4 ± 3.9. Of them,
72% were stage I and the rest were more advanced. Various
clinical features evaluated by DESS were compared between
patients at mild stage (I) and advanced stage (II-IV). More
than 10 features had higher DESS scores in patients at
advanced stage (P < 0.05 or 0.01; Table 1). The mean rank
of total scores of patients at advanced stage was also signifi-
cantly higher than that at mild stage (24.3 in advanced stage
group versus 16.3 in mild stage group, P =0 . 0 4 ) .
Correlation between DESS scores and other clinical
staging systems
To better validate the value of DESS, patients were also
staged using other 4 clinical staging systems: Liver Can-
cer Study Group of Japan/Tumor-Node-Metastasis Sta-
ging System(TNM/LCSGJ) [27], Child-Pugh Grading
System [28], Barcelona Clinic Liver Cancer Staging Sys-
tem (BCLC) [29], and Cancer of Liver Italian Program
Score (CLIP) [30]. The latter four systems are widely
applied for the evaluation of liver cancer. Details of
comparison between systems were summarized in Table
2. Significant and positive correlation between DESS
and other staging systems was found (P < 0.05 or 0.01;
Table 2). There was a significant and strongest correla-
tion between BCLC and DESS (r = 0.501, P =0 . 0 0 2 ) ,
while not between Child-Pugh Grade and DESS.
Figure 2 Frequencies of peripheral regulatory B cells of
different study groups. Frequencies of peripheral regulatory B
cells were analysed in the healthy donor (Healthy), patients with
chronic hepatitis B infection (CHB), and patients with hepatocellular
carcinoma (HCC) before surgery (HCCb), 1-2 days (HCCa1) or about
7 days (HCCa7) after surgery. Representative flow cytometry analysis
of peripheral IL10
+CD19
+ cells were measured and presented (A).
Frequency of IL10
+CD19
+ cells of total CD19
+ B cells in the
peripheral blood (B). The mean ± SEM is shown, *, **and *** stand
for P < 0.05, 0.01 and 0.001 respectively.
Figure 3 Perioperative kinetics of peripheral lymphocytes of
patients with hepatocellular carcinoma. Frequency (A) and
numbers (B) of lymphocytes in patients with hepatocellular
carcinoma (HCC) before surgery (HCCb), 1-2 days (HCCa1) or about
7 days (HCCa7) after surgery. The mean ± SEM is shown, ** and ***
stand for P < 0.01 and 0.001, respectively.
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Tregs and Bregs
Correlations of frequencies of peripheral Tregs and
Bregs with DESS scores of clinical features were further
examined in HCC patients (Table 3). High frequency of
circulating Tregs was significantly correlated with the
history of HBV infection (P = 0.031), circulating leuko-
cytes (P = 0.029). The history of weight loss, plasma
levels of ferritin, portal vein tumor thrombosis, hepatic
vein invasion, and clinical stages evaluated by TMN sys-
tems or BCLC scores(P< 0.05 or 0.01; Table 3) were
inversely associated with frequency of circulating Tregs.
At the same time, frequency of circulating Bregs has a
positive correlation with HBeAg (P = 0.03) and HBV
DNA copy number to some extent (P = 0.028).
Discussion
Tregs, as a functionally unique subgroup of T lympho-
cytes, can suppress effective antitumor immune
responses of various malignancies, including HCC
[31,32]. The higher infiltration of Tregs in the local
tumor microenvironment was found to correlate with
poor prognosis of patients with HCC [3]. Likewise,
increased frequency of peripheral Tregs was also shown
to correlate with poor outcome [33]. However, unlike
intratumoral Tregs, which were consistently reported to
be increased in HCC patients, descriptions about fre-
quency of peripheral Tregs were uncertain [5,6,34].
Since CD4
+CD25
+CD127
- was proved to be a classic
surface marker for purified Tregs with highly suppres-
sive function [35], Tregs were identified with CD4
+CD25
+CD127
- in the present study. Bregs are another
special class of regulatory lymphocytes that modulating
immune response. They have been suggested to be
engaged in repressing autoimmune disease, chronic
inflammatory diseases [13,14] and promoting tumor
progression [16,18]. However, most current studies
about Bregs were conducted in animal models and little
was known on disease specific patterns of peripheral
Bregs in HCC patients. In this study, we investigated the
dynamic frequencies of both peripheral Tregs and Bregs
among HCC patients during the perioperative period.
Our data showed that the peripheral frequency of
Tregs in HCC patients before surgery was significantly
lower than control groups, but increased after tumor
resection. No statistical difference were found between
Table 1 Difference of clinical features between HCC
patients at low and high stages of TNM (AJCC).
Variables Mean Rank P
Stage
Low
Stage
High
Platelet ×10
9/L 16.77 23.00 0.034
Thrombocytocrit % 17.19 21.90 0.027
Cystatin C mg/L 16.08 24.80 0.003
Albumin/Globin 16.38 24.00 0.032
High density lipoprotein mmol/L 15.88 25.30 0.001
a-fetoprotein ng/ml 16.46 23.80 0.046
Ferritin ng/ml 15.62 26.00 0.004
Numbers of up-regulated tumor
markers
15.48 26.35 0.003
Multiple Satellite nodules 16.77 23.00 0.053
Tumor encapsulation 16.88 22.70 0.022
score of Pathology section 15.58 26.10 0.007
Score of Tumor markers 16.35 24.10 0.042
Total score 16.27 24.30 0.040
Stage low: TNM (AJCC) stage I. Stage high: TNM (AJCC) stage II-IV.
HCC: Hepatocellular carcinoma; TNM (AJCC): Tumor-Node-Metastasis Staging
System (American Joint Committee on Cancer).
Table 2 Correlations between total DESS scores and
clinical stages of HCC patients.
Total DESS scores
Staging system rP
TNM (AJCC) stage 0.365 0.029
TNM (lCSGJ) stage 0.364 0.029
CLIP score 0.474 0.004
BCLC stage 0.501 0.002
Child-Pugh grade -0.121 0.482
DESS: Digital evaluation scoring system; HCC: Hepatocellular carcinoma; TNM
(AJCC): Tumor-Node-Metastasis Staging System (American Joint Committee on
Cancer); TNM (LCSGJ): Tumor-Node-Metastasis Staging System (Liver Cancer
Study Group of Japan); CLIP: Cancer of the Liver Italian Program Score; BCLC:
Barcelona Clinic Liver Cancer Staging System.
Table 3 Correlations of clinical features of HCC patients
with circulating Tregs and Bregs.
DESS evaluated Tregs Bregs
Clinicopathological Characteristic rPr P
Weight Loss -0.339 0.043* - -
HBV Infection History 0.360 0.031* - -
Leucocyte 0.363 0.029* - -
Hepatitis B e Antigen - - 0.527 0.030*
HBV DNA Copy number - - 0.532 0.028*
Ferritin -0.451 0.006** - -
Numbers of up-regulated tumor markers
#
-0.376 0.024* - -
Portal vein tumor thrombosis -.408* 0.014* - -
Hepatic vein invasion -.413* 0.012* - -
BCLC score -0.443 0.007** - -
TNM stage(AJCC) -0.347 0.038* - -
(*, ** stands for P < 0.05, 0.01, respectively)
# Tested tumor markers:a-fetoprotein; cancer antigen 125; cancer antigen 153;
cancer antigen 199; Ferritin; Carcino-embryonic antigen; prostate specific
antigen.
HCC: Hepatocellular carcinoma; Tregs: Regulatory T cells; Bregs: Regulatory B
cells; HBV: Hepatitis B virus; BCLC: Barcelona Clinic Liver Cancer Staging
System; TNM (AJCC): Tumor-Node-Metastasis Staging System (American Joint
Committee on Cancer).
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that comparatively lower levels of peripheral Tregs in
HCC patients may be associated with HCC itself, rather
than the chronic inflammatory phase. One hypothesis
forwarded includes recruitment of peripheral Tregs to
the local environment[36]. The migration of peripheral
Tregs in HCC patients has been suggested to be related
to the production of chemokines from HCC [37].
The present results demonstrated that the peripheral
frequency of Bregs was higher in CHB patients as com-
pared with healthy donors and HCC patients. It is possi-
ble that the systemic inflammatory state caused by
hepatitis induces the expansion of peripheral Bregs.
Similarly, the frequency of Bregs was dramatically
increased in HCC patients after surgery, with the level
higher than CHB patients 7 days following resection. To
our knowledge, we are the first to show the periopera-
tive dynamic changes to circulating Tregs and Bregs in
HCC patients and found a similarly increased pattern of
them after radical surgery. Further studies are needed to
clarify such elevation is resulted from the removal of
tumor or extensive liver surgery.
HCC may produce abundant disease specific cytokines
and chemoattractants including IL-8 [38] and CCL 20
[37], some of which are responsible for the “homecom-
ing” signals to orient regulatory lymphocytes into the
tumor. After surgery, Tregs and Bregs may be tempo-
rally stocked in the peripheral circulation due to the
descent of tumor chemoattractants. Bregs play an
important role in the prevention of inflammation, auto-
immune response [39,40] and antitumor effects [17].
Hence, Bregs are probably involved in the local balance
of immune tolerance and immune suppression in HCC
like Tregs. To clarify the disease-specific dynamic profile
of Tregs and Bregs in HCC, perioperative frequency of
peripheral Tregs and Bregs in patients with pancreatic
cancer was also measured. We found similar pattern but
relatively altered degree of Tregs and Bregs in patients
with pancreatic cancer (data unshown).
Accumulating evidences showed interaction between
Tregs and Bregs in tumor microenvironment. For exam-
ple, Bregs in the lung metastasis from breast cancer
have been reported to induce conversion of resting CD4
+T cells to Tregs to support metastatic growth. These
tumor-evoked Bregs express constructively activated
stat3 and B7-H1 [16]. In additions, Bregs are involved in
anti-inflammatory process through the promotion of
Tregs in HCC, like those reported in autoimmune dis-
ease [41]. Our previous work discovered that the expres-
sion of B7-H1 and IL10 was up-regulated in HCC
tissues [42]. Similar interactions between Breg and
Tregs mentioned above may exist in human HCC devel-
opment as well. Collectively, the postoperative increase
of peripheral Tregs and Bregs in HCC patients might
worsen the host immune system due to their established
immune suppressive capabilities after surgery. This
immunopathological condition of body caused by regu-
latory lymphocytes will promote tumor metastasis and
recurrence. This could also partially explain the unsatis-
factory outcome of HCC patients who even received
radical surgery. Strategies against Tregs have been
proved to enhance anti-cancer immunity [43]. Elimina-
tion of Bregs have also been suggested to be useful in
the clearance of established tumor[44]. Therefore, a
comprehensive adjuvant immunotherapy targeting both
Tregs and Bregs may be beneficial for improving prog-
nosis of post-surgery HCC patients.
Total number and percentage of circulating lympho-
cytes were initially deceased after surgery, but recovered
within a week. During this period, a rapid proliferation
of lymphocytes may occur. It was found that stem cells
including mesenchymal stem cells could proliferate after
surgery. Various growth factors produced by stem cells
like heme oxygenase-1 could stimulate the expansion of
Tregs and Bregs [45].
The application of clinical informatics made it easier to
analyse the correlation between extensive clinical pheno-
types and frequencies of peripheral Tregs and Bregs. Ferri-
tin released by melanoma was reported to induce IL10
production of lymphocytes and suppress immune
responses [46]. We found serum ferrtin levels were corre-
lated with circulating Tregs in HCC patients supporting
previous studies. In addition, the negative correlation of
Tregs with up-regulation of a panel of routinely tested 8
tumor markers(a-fetoprotein, cancer antigen 125, cancer
antigen 153, cancer antigen 199, ferritin, carcino-embryo-
nic antigen, prostate specific antigen) has been discovered.
Intratumoral Tregs were found to be positively correlated
with vascular invasion [3]. In contrast, our data further
demonstrated that the frequency of peripheral Tregs was
correlated with portal vein thrombosis and hepatic vein
invasion, supporting its connection with HCC aggressive-
ness. We found frequency of peripheral Bregs was posi-
tively correlated with HBeAg and HBV DNA copy
numbers. These indicate that active HBV infection may
stimulate the accumulation of circulating Bregs. To further
explore the mechanism associated with the interactions
between Tregs and Bregs, mediators from both regulatory
cells should be profiled and validated. Network biomarkers
depicting protein-protein interactions within both regula-
tory cells should be investigated by the integration of
knowledge on protein annotations, interaction, and signal-
ling pathway [47,48]. Dynamic network biomarkers should
be further correlated with clinical informatics, thereby to
select not only disease specific but also disease stage speci-
fic biomarker [49]. DESS as a useful tool of clinical infor-
matics can be modified leading to extensive clinical
application in future [19].
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We report that frequencies of both peripheral Tregs and
Bregs in HCC patients were decreased before surgery
and significantly elevated after resection. These results
suggest that a postoperative combined strategy targeting
Tregs and Bregs could be beneficial for HCC patients to
improve their prognosis. The correlations discovered
between peripheral regulatory lymphocytes and clinical
features through DESS set an example of clinical trans-
lational medicine.
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